Iron Deficiency and Hereditary Haemorrhagic Telangiectasia

Iron Deficiency and Hereditary Haemorrhagic Telangiectasia

Sponsors

Lead Sponsor: Imperial College London

Source Imperial College London
Brief Summary

Managing iron deficiency is important for more than 1 billion individuals worldwide, to avoid blood transfusions, or excessive strain on vital organs that depend on iron-containing haemoglobin to deliver oxygen to the tissues. Iron deficiency is a particular problem for people with the inherited condition hereditary haemorrhagic telangiectasia (HHT). Their iron deficiency and anaemia results from blood losses, especially from the nose (nosebleeds, and they often need additional iron to replace that lost through bleeding.

Our goal is to stratify HHT patients into high/low absorbers of iron; to define what extra iron they need to adjust for their current and likely future blood losses; and to work out how to achieve this most safely for each individual to improve their later health.

We will test the hypothesis that informed assessment of iron intake and post absorption cellular profiles changes the recommendations for iron intake for HHT patients.

Detailed Description

Relevant patients due to come to clinic or the programmed investigation unit will be offered the opportunity to participate in the study.

Up to 100 consenting individuals will

- have an additional 15 mls of supplementary research bloods taken

- receive a single tablet of ferrous sulphate 200mg

- fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months

- have a second blood sample later that day (20 mls of blood)

The primary outcome measure is the change in serum iron levels post iron tablet.

Other outcome measures will include:

- Haematinic indices indicating whether their iron requirements have been met previously.

- Additional predicted iron intake requirements to adjust for haemorrhagic iron losses

Overall Status Terminated
Start Date July 2013
Completion Date July 2015
Primary Completion Date July 2015
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Blood iron indices 4-5 hours after iron tablet ingestion
Enrollment 3
Condition
Intervention

Intervention Type: Drug

Intervention Name: Ferrous sulphate 200mg oral tablet

Description: Administration by mouth

Arm Group Label: Iron treatment

Other Name: Iron tablet

Eligibility

Criteria:

Inclusion Criteria:

- Hereditary haemorrhagic telangiectasia (HHT). Definite diagnosis of HHT by international criteria.

- No iron tablets or treatment taken on day of assessment

- Ability to provide informed consent.

Exclusion Criteria:

- Inability to provide informed consent

- Intercurrent infection or illness predicted to modify iron absorption.

- Needle phobia.

Gender: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Claire L Shovlin, PhD FRCP Principal Investigator Imperial College London
Location
Facility: Wellcome Trust-McMichael Clinical Research Facility, Imperial college London London, United Kingdom W12 0NN
Location Countries

United Kingdom

Verification Date

October 2019

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Iron treatment

Type: Experimental

Description: INTERVENTION: Ferrous sulphate 200mg oral tablet This is a single arm study. Individuals in this arm will have an additional 15 mls of supplementary research bloods taken with their usual clinic bloods receive a single tablet of ferrous sulphate 200mg fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months have a second blood sample later that day (20 mls of blood Total number of participants in arm = 100

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov